Although it is currently unclear whether IL-6 inhibition has similar benefits in other cases of sepsis, a recent Mendelian randomization analysis suggests that IL-6 receptor blockade was associated with lower mortality in 11,643 patients of the UK Biobank cohort with non-COVID-19 sepsis [25]. The gene discussed is IL6; the disease is Sepsis.